Explore Investments/Jeff Bezos report 6.6% stake in Lyell (LYEL)
Explore Investments LLC and Jeffrey P. Bezos have reported a 6.6% beneficial ownership stake in Lyell Immunopharma, Inc. (LYEL), totaling 1,529,054 shares. This disclosure was made via a Schedule 13G/A filing, with Mr. Bezos identified as the sole member of Explore Investments LLC and thus deemed a beneficial owner. The percentage is calculated based on 23,328,390 outstanding shares as of March 31, 2026, as per Lyell's preliminary prospectus.
MAY 7·Barchart.com▼
Lyell Immunopharma: Q1 Earnings Snapshot
Lyell Immunopharma Inc. (LYEL) reported a first-quarter loss of $24.2 million, translating to $1.10 per share. The biotechnology company, based in South San Francisco, California, also reported revenue of $2,000 for the period. This financial summary was generated using data from Zacks Investment Research.
MAR 13·IndexBox▼
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4M - News and Statistics
Lyell Immunopharma reported a net loss of $140.7 million for the final quarter of 2025, with revenue totaling $6,000. For the full fiscal year 2025, the company announced an annual net loss of $274.4 million and annual revenue of $36,000. This financial update includes a comprehensive report on the antisera industry in the United States, detailing market dynamics, trade flows, and forecasts to 2035.
